Savara Newsroom

Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating

MT NewswiresJun 27 11:24 ET

Savara Analyst Ratings

BenzingaJun 26 13:31 ET

Savara Analyst Ratings

BenzingaMay 21 08:01 ET

Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)

TipRanksMay 21 07:55 ET

Savara Analyst Ratings

BenzingaMay 16 13:02 ET

Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)

TipRanksMay 13 07:05 ET

Savara Analyst Ratings

BenzingaMay 13 06:42 ET

Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)

TipRanksMay 10 08:00 ET

Savara Analyst Ratings

BenzingaMay 6 11:11 ET

Optimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial Success

TipRanksMay 3 00:30 ET

Savara Analyst Ratings

BenzingaApr 19 12:30 ET

JMP Securities Reiterates Market Outperform on Savara, Maintains $8 Price Target

BenzingaApr 19 12:30 ET

Savara Analyst Ratings

BenzingaApr 18 13:37 ET

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)

TipRanksApr 18 00:35 ET

Optimistic Buy Rating for Savara Based on Molgramostim's Market Potential and Study Outcomes

TipRanksApr 9 08:11 ET

Savara Analyst Ratings

BenzingaMar 11 06:51 ET

Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)

TipRanksMar 8 07:56 ET

Optimistic Buy Rating for Savara on Molgramostim's Market Potential and Strong Financials

TipRanksMar 8 00:35 ET

Savara Analyst Ratings

BenzingaMar 4 08:17 ET

Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)

TipRanksMar 4 08:06 ET